DCPX.F Stock Overview
A biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing therapeutic cannabinoids in various disease areas.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
DanCann Pharma A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 0.01 |
| 52 Week High | DKK 0.01 |
| 52 Week Low | DKK 0.01 |
| Beta | 1.94 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0% |
Recent News & Updates
Recent updates
Shareholder Returns
| DCPX.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -0.3% | 0.07% |
| 1Y | n/a | 17.1% | 20.7% |
Return vs Industry: Insufficient data to determine how DCPX.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how DCPX.F performed against the US Market.
Price Volatility
| DCPX.F volatility | |
|---|---|
| DCPX.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.9% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DCPX.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine DCPX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 10 | Jeppe Rasmussen | www.dancann.com |
Dancann Pharma A/S, a biopharmaceutical company, focuses on discovering, developing, manufacturing, and commercializing cannabinoid therapeutics in various disease areas. The company produces and distributes prescription and over-the-counter cannabinoid-based pharmaceuticals primarily focused on pain patients. Dancann Pharma A/S was incorporated in 2018 and is based in Ansager, Denmark.
DanCann Pharma A/S Fundamentals Summary
| DCPX.F fundamental statistics | |
|---|---|
| Market cap | US$1.83m |
| Earnings (TTM) | -US$1.78m |
| Revenue (TTM) | US$1.03m |
1.8x
P/S Ratio-1.0x
P/E RatioIs DCPX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCPX.F income statement (TTM) | |
|---|---|
| Revenue | DKK 7.15m |
| Cost of Revenue | DKK 10.61m |
| Gross Profit | -DKK 3.46m |
| Other Expenses | DKK 8.88m |
| Earnings | -DKK 12.34m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.074 |
| Gross Margin | -48.32% |
| Net Profit Margin | -172.53% |
| Debt/Equity Ratio | 0% |
How did DCPX.F perform over the long term?
See historical performance and comparison